Navigation Links
New data on highly effective treatment for chronic rhinosinusitis with nasal polyps
Date:12/1/2009

December 1, 2009: OptiNose is pleased to announce the publication of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the topical treatment of chronic rhinosinusitis with nasal polyps in Rhinology, the official journal of the International and European Rhinologic Societies.

Chronic rhinosinusitis with nasal polyps is a chronic disease that can significantly reduce a patient's quality of life, causing facial pressure and pain, nasal obstruction and reduced sense of smell. The novel OptiNose device delivers drugs to target sites deep in the nose, including the sinus openings where nasal polyps emerge. These targets are often difficult to reach with traditional nasal sprays.

In the Phase II study conducted by OptiNose, patients in the active treatment group experienced highly significant reductions in polyp size compared to placebo with corresponding significant and progressive improvements of all symptom scores including rhinitis symptoms, nasal discomfort and sense of smell. At the conclusion of the study, the polyps had disappeared in 10 out of 54 patients in the active group, whereas polyps were still present in all patients in the control group.

The multicenter, placebo-controlled study, conducted in 109 patients with mild-to-moderate bilateral nasal polyposis, assessed the efficacy, safety and tolerability of 400 micrograms of fluticasone propionate delivered twice daily with OptiNose's liquid nasal drug delivery device over a 12 week period. Reduction in polyp size was measured using Lildholdt's Scale, a 4-point scale used to rate the size of nasal polyps. A significantly greater percentage of subjects using the OptiNose product showed a reduction in polyp size greater than or equal to 1 on the Lildholdt's Scale when compared to placebo at 4, 8 and 12 weeks (22% vs 7%, p = 0.011; 43% vs 7%, p < 0.001; 57% vs 9%, p < 0.001). The summe
'/>"/>

Contact: Helena Djupesland
Helena.Djupesland@optinose.no
472-295-8017
WFD Ventures
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists unravel evolution of highly toxic box jellyfish
2. LMU Munich researchers highly endowed with EU funding
3. Forsyth receives highly competitive challenge grants
4. Duke biomedical scientists win 2 highly prized NIH Directors Awards
5. Lancet study supports new, highly effective treatment for blood disorder
6. New population of highly threatened greater bamboo lemur found in Madagascar
7. Slow-motion video study shows shrews are highly sophisticated predators
8. The key to unlocking the secret of highly specific DNAzyme catalysis
9. 454 Sequencing: Science paper describes a novel, highly efficient method of sequencing ancient DNA
10. A sticky solution for identifying effective probiotics
11. Carnegie Mellon customizing electric cars for cost-effective urban commuting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... provide statin drugs free of charge so that customers can ... Imperial College London suggest in a new study published this ... in the blood. A wealth of trial data has proven ... attack risk. In a paper published in the Sunday ...
... Mount Sinai School of Medicine, New York, has been ... receive a 2010 ICAAC Young Investigator Award. Sponsored ... an early career scientist for research excellence in microbiology ... postdoctoral training in Molecular Biology at Harvard University in ...
... 250 scientists, engineers, government advisers and groups concerned ... from August 15-20, 2010 to consider the impact ... University of Maryland is co-sponsoring the conference, The ... ), which is co-organized by University of Maryland ...
Cached Biology News:Free statins with fast food could neutralize heart risk, scientists say 2University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life 2University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life 3
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced ... at the Bank of America 2008 Specialty,Pharmaceuticals Conference ... at the,Southampton Inn, Long Island, NY., The ... can be,accessed under "Calendar of Events" in the ...
... 31 Vista Partners announced today,that it has ... which target billion dollar markets, are progressing through,the ... present Phase 2 results for,Convivia(TM) sometime in the ... approval,of Delayed Release (DR) Cysteamine for the treatment ...
... OTTAWA, July 31 /PRNewswire-FirstCall/ - iNutrition, Inc., (http://www.inutrition.com ... Bars, its,new all natural line of nutrition bars. ... and come in three varieties; Fission Fruit, Fission,Energy, ... of,real, delicious fruits, Fission Bars have no refined ...
Cached Biology Technology:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) 2iNutrition Launches New Fission Fruit Nutrition Bars 2
...
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
... Fixed Angle Polypropylene Rotor designed for ... Centra CL3/CL3R** and Centra-MP4/MP4R*. A translucent ... /MP4, ,EXCLUSIVE polypropylene rotor design provides ... repeatedly autoclaved. Polypropylene rotors are ...
... Forma stacking shakers have the ... speed stacked 3-high, and the ... sensitive "soft shake" applications. ... and systems, our stackers are ...
Biology Products: